imvanex
bavarian nordic a/s - breytt bóluefni ankara - bavarian nordic (mva-bn) veira - smallpox vaccine; monkeypox virus - Önnur veiru bóluefni, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.
mvabea
janssen-cilag international n.v. - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.
tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - veirueyðandi lyf til almennrar notkunar - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 og 5. tecovirimat siga should be used in accordance with official recommendations.
daktacort krem
mcneil sweden ab - miconazolum nítrat; hydrocortisonum inn - krem
hydrocortison med terramycin og polymyxin b eyrna-/augndropar, dreifa
pfizer aps - polymyxinum b súlfat; oxytetracyclinum hýdróklóríð; hydrocortisonum acetat - eyrna-/augndropar, dreifa
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - yfirborðs mótefna gegn inflúensuveiru (haemagglutinin og neuraminidasa) á stofn a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirgerð inflúensu a veiru. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - bóluefni - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - bóluefni - active immunisation against h5 subtype of influenza a virus.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant inflúensu veira (lifandi, bæklaða) eftir álag: a/víetnam/1203/2004 (h5n1) álag - inflúensu, manna - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið í börn og unglingar frá 12 mánuði til að minna en 18 ára aldri. faraldur inflúensu h5n1 astrazeneca ætti að vera notuð í samræmi við opinbera leiðsögn.
pandemic influenza vaccine h5n1 baxter ag
resilience biomanufacturing ireland limited - inflúensubóluefni (heil veiru, óvirkt) sem inniheldur mótefnavaka af: a / víetnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið. bólusetning gegn heimsfaraldri inflúensu ætti að nota í samræmi við opinbera leiðbeiningar.